Pharma Focus Asia

Thermo Fisher Expands Cell Culture Media Site in New York

Introduction:

Thermo Fisherpalns for the expansion of new dry powder media manufacturing facility.The facility is expanded to support the production of raw materials used for the manufacturing of  new vaccines and biologic therapies.

Features:

The new expanision adds 45,000 square feet of Animal Origin Free (AOF) manufacturing space.

The new exapsnion is a part of US$650 million multi year investment project to support worldwide supply of media. Moreover, it advances the existing site capabilities to manufacture materials and technology required for the creation of commercial production of new vaccines and biologics including COVID-19 vaccines.

This expanion will address the urgernt supply of raw materials, by providing production redundancy and shorten product manufacturing lead times for customers.The new facility is expected to double the total bioprocess manufacturing capacity by the end of 2023.

The expansion creates more than 100 new jobs for staff across operations, manufacturing, R&D, operations, HR, engineering, and maintenance.

Specifications:

NameThermo Fisher
TypeExpansion
Year2023
magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024